智通财经APP讯,联康生物科技集团(00690)发布公告,下列事项自2024年11月1日起开始生效:张清已获委任为非执行董事。
此外,公司应根据其于2016年9月28日采纳的购股权计划向张清授出5000万份购股权(每份赋予承授人认购公司股本中1股每股面值0.01港元的股份的权利)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.